Abstract LB-502: Development of three dimensional cancer cell-CAF co-culture system

Abstract

Abstract Purpose A large number of cell lines have been established and used for cancer research. Monolayer culture of cancer cells alone is a simplified and effective method, however, it does not always reflect the physiological conditions. In this study, we tried to establish a simple co-culture method of cancer cells and CAF (cancer associated fibroblast), to develop three dimensional model of stroma rich tumor with cells such as pancreatic cancer and scirrhous cancer. Method Human tumor tissue samples were obtained from patients who had undergone surgery at the National Cancer Center Hospital East, Japan. Written informed consents were obtained from all patients. BxPC-3 (pancreatic cancer cell line) and A549 (lung cancer cell line) were stained with red-fluorescent dye, PKH-26. Pancreatic cancer derived- and lung cancer derived-CAF were stained with green-fluorescent dye, PKH-67. Cancer cells and CAF are seeded into the microtiter plates for 3D cell culture (NanoCulture® Plate) at a same cell number, and spheroid formation was measured by a fluorescent time lapse microscopy for 3-days. Result BxPC-3 (red) and Pancreatic CAF (green) merged well and formed mosaic spheroids. BxPC-3 (red) and lung CAF (green) did not merge and separately formed spheroids of each cell types. A549 and lung CAF merged, but A549 and Pancreatic CAF did not merge clearly. It is suggested that a specific recognition mechanisms exist by organ types or tumor types, with the adhesion between cancer cell and CAF. A) BxPC-3 and Pancreatic CAF B) BxPC-3 and lung CAF Conclusion In this study, mosaic spheroid were formed by co-culturing of same organ derived cancer cells and CAF. This co-culture system is expected as an effective tool for cancer microenvironment study and/or drug screening targeting with stroma rich tumor. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-502. doi:1538-7445.AM2012-LB-502